Clashing Convictions Of Taliban And The West Is Costing Afghan Lives - Health Policy Watch

While health-related barriers to workforce participation cost Canada more than $100 billion in economic output in 2025, reducing those barriers by 25 per cent could recover more than $25 billion annually, according to a new report by Deloitte Canada. “I don’t think the connection between health and the economy is necessarily new,” says Michelle Theroux, national health leader at Deloitte Canada. “But $25 billion is a lot of money. . . . We do believe health belongs on the competitiveness agenda and should be treated with the same discipline and measurement rigor that the country applies to trade, capital and other types of investments related to the economy.”

Bioengineer.org news storyFor people living with HIV, modern antiretroviral therapy can suppress the virus to levels below what standard laboratory tests can detect. Yet some patients on long-term treatment experience a curious phenomenon: a single test result showing a small, transient amount of virus in the blood, followed by an immediate return to undetectable levels. These events, known as viral blips, have puzzled clinicians and researchers for years, raising questions about whether they represent harmless statistical noise, brief bursts of viral production from hidden reservoirs, or early warnings of impending treatment failure. A new nationwide Swedish study, published in BMC Infectious Diseases, offers one of the most comprehensive answers to date. Drawing on the Swedish national InfCareHIV cohort, researchers analyzed data from 4,210 treatment-naïve adults who began antiretroviral therapy from 1 January 2007 onward, with follow-up data extracted through 30 September 2020. The median observation time was 5.5 years, with some individuals followed for as long as 13.7 years.